Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.45 |
| ▸ | MGMT | P16455 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2255723 | 0.86 | EGFR (0.47) | EGFRERBB2GAK | |
| SCHEMBL141513 | 0.85 | EGFR (0.44) | EGFRERBB2MEN1KMT2AGAK | |
| SCHEMBL2250951 | 0.82 | EGFR (0.50) | EGFRERBB2GAK | |
| SCHEMBL2949280 | 0.82 | EGFR (0.44) | EGFRERBB2GAK | |
| SCHEMBL29555766 | 0.80 | EGFR (0.59) | EGFRERBB2MGMTMEN1KMT2A | |
| SCHEMBL141880 | 0.80 | EGFR (0.59) | EGFRERBB2MGMTMEN1KMT2A | |
| SCHEMBL2952629 | 0.80 | EGFR (0.53) | EGFRERBB2MEN1KMT2AGAK | |
| SCHEMBL2943738 | 0.79 | EGFR (0.46) | EGFRERBB2GAK | |
| SCHEMBL2251628 | 0.77 | EGFR (0.45) | EGFRERBB2GAK | |
| SCHEMBL2950338 | 0.77 | EGFR (0.46) | EGFRERBB2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, ERBB2, FLT3 | EGFR 8/4885ERBB2 2/4885ABCG2 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.